Background: Inflammatory Bowel Disease (IBD) imposes a heavy psychosocial burden, with many patients
INTRODUCTION
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), can have burdensome psychosocial consequences for those with the condition 1 including distress related to symptoms 2 . Distress may be understood as an 'emotional anguish or suffering' 3 , or as 'a non-specific, biological or emotional response to a demand or stressor that is harmful to the individual' 4 .
Disease-related distress has been identified and researched extensively in other chronic conditions including diabetes [5] [6] [7] [8] [9] , asthma 10, 11 , cancer [12] [13] [14] and multiple sclerosis 15 . Earlier work from this study team has identified and reported the phenomenon in people with IBD 16 . Studies reporting 'psychological distress'
in IBD have often measured only anxiety and depression 17, 18 , although evidence from diabetes 19 , cancer 13 , and multiple sclerosis 15 demonstrates that whilst it may be related, disease-related distress is distinct from anxiety and depression 6 . However, unlike anxiety and depression, disease specific distress is not a diagnosable condition in the DSM Manual of Psychiatric Diagnoses 20 . Disease-specific distress is a spectrum of emotional experience relating to the disease being experienced by the person 21 . In IBDdistress we define this as the person's experience of feeling overwhelmed by the demands of living with and managing their condition. We hypothesize its distinctiveness from anxiety and depression in that it is uniquely focused in emotional response to disease experience and not generalized to other psychological morbidities. In diabetes, an analysis of the clinical notes of 40 people with elevated distress diabetes estimated that 30% had an additional underlying co-morbid anxiety and/or depression with the majority 70% demonstrating no signs of psychological co-morbidity but experiencing disease specific distress alone 22 . Disease-specific distress could therefore be defined as 'an emotional response to the burden of chronic illness symptoms which may share symptoms of anxiety and depression, but is not diagnosed as such and is attributable only to the emotional response to disease experience'.
Cut offs for elevated distress have been established in diabetes [23] [24] [25] . Elevated diabetes distress is associated with higher blood glucose levels and fewer self-care behaviours such as medication concordance and disease monitoring 19 . Addressing diabetes distress improves clinical outcomes in interventional studies in type 1 and type 2 diabetes and in adolescents 8, 9 and this may be important for IBD as well, where the problems of concordance with oral medications are also recognised 26, 27 . The higher prevalence of symptoms of anxiety and depression in people with IBD, when compared to the general population, is well established [28] [29] [30] yet the presence and impact of IBD-distress remains under-explored.
There are no tools to assess IBD-distress in IBD patients, and it is likely to be poorly identified and so support may not be offered. An assessment tool for IBD distress may evidence the need for additional support, and in the longer term has the potential to improve patient quality of life and self-management in IBD.
In preliminary work, we collaborated with our Patient and Public Involvement (PPI) group to identify the presence and impact of IBD-related distress, through secondary analysis of existing qualitative data from our previous studies addressing fatigue, stigma, and incontinence in IBD [31] [32] [33] [34] . By comparing the findings with the domains of the Diabetes Distress Scale (4), we identified that people with IBD have many similar, but some unique disease-related sources of distress. In previously published work we confirmed findings via a patient focus group (n=8) and a clinician Delphi study (n=20), resulting in 94 items that could be used to assess IBD distress. These were contained in five distinct domains of emotional, healthcare-related, interpersonal / social, treatment-related and symptom-related distress 16 . This paper builds on our earlier
work and reports refinement of the 94 item IBD-DS into the final 28 item IBD-DS; it also reports comparison with a gold standard scale for diabetes distress 35 and with a scale for symptoms of anxiety and depression 36 , and determines the new scale's face, content and construct validity, and reliability via test-retest 37 in people living with IBD.
MATERIALS AND METHODS
Following preliminary work reported elsewhere 16 , we conducted a three-phase study guided by recommended procedures for development of a patient reported outcome measure (PROM) 38 . increasing with the number of items to be tested 42 , but an accepted 'rule of thumb' indicates 10 participants per item although this has never been verified 43, 44 .
Data collection tools
Demographic data (age, gender and IBD diagnosis) were collected from all participants. In Phases 2 and 3, disease activity was self-assessed by participants using the Crohn's Disease Activity (Harvey Bradshaw) Index (HBI) 45 for those with CD, and the Simple Clinical Colitis Activity Index (SCCAI) 46 for those with UC.
We have successfully collected remote patient completion of the HBI and SCCAI in previous studies 32, 41 . A disease activity score of 4 or below indicated remission, whilst a score of 5 or above indicated relapse. 
Patient and Public Involvement
A patient and public involvement (PPI) team of two men and two women with IBD was recruited from the membership of the funding charity, and from a UK IBD charity. The team had significant involvement in the preliminary work to identify distress in IBD 16 . In this study, they participated in designing the layout of the new IBD Distress Scale, in the item reduction process after the Phase 1 cognitive interviews and in planning dissemination activities. PPI involvement in research is widely encouraged and potential benefits of the role of PPI in PROM development have been reported 47 . These benefits reflect those seen in clinical trials and other engagement projects -including 'increasing the quality and quantity of patient relevant priorities and outcomes' 48 .
Data collection
An overview of the full development and testing process is provided in Fig.1 .
Phase 1: IBD-DS item generation and item reduction (Fig.1 Box A)
Development of patient-reported measures usually begins by interviewing people with the condition of interest to identify potential content 38 . Our preliminary work 16 , which provided 94 items for the first draft of the new Inflammatory Bowel Disease Distress Scale (IBD-DS), replaced this stage.
Establishing face and content validity (Fig.1 Box B)
Addressing face validity (the ease with which the completing person can understand each question) and content validity (the relevance of questionnaire content) are the next stages in developing a new questionnaire 38 . During an initial three rounds of cognitive interviews (n=15), face and content validity of the 94-item draft IBD-DS were explored. Cognitive interviews are used to detect problems participants may have in understanding / interpreting the questions, and in being able to give the response they wish to give 49 . Attention is also paid to grammar, layout, ease of use and item completion rate, using 'think aloud' and verbal probing techniques 50 . Cognitive interviews help to identify ambiguous or misleading questions, and whether the response and scoring options are appropriate. These initial 15 interviews were digitally audiorecorded, and transcribed. Between interview rounds, revisions were made to the developing IBD-DS, using simple thematic analysis of transcripts and notes, and discussion between three of the authors (LD, CN, SW).
Initial item reduction (Fig. 1 Box C)
Over three interview rounds, the draft IBD-DS was reduced from 94 to 88 items and wording was refined.
The study team, including PPI representatives, conducted a simple analysis of the spread of responses from each participant. Twenty-four questions were deleted and 15 were combined to create six new questions. In response to interview participants' comments, the rating scale was amended from 0-10, to 0-6. Three supplementary unscored questions were added: a 0 -6 scale for current overall level of distress (0 = not distressed; 6 = highly distressed); a scale for reporting perceived current level of disease activity (in remission; mild flare; moderate flare; severe flare); and a free-text item for prioritizing their top three current causes of distress.
The 55 item draft IBD-DS was then tested via three further cognitive interviews ( Fig. 1 Box D) . No further substantive changes were required, confirming a 55-item draft IBD-DS (each item scored 0-6, score range 0-330), plus three supplementary unscored questions.
Phase 2

Determining construct validity and reproducibility (Fig.1 Box E)
Our aim was to determine how well the 55 item draft IBD-DS performed by assessing response rates to individual questions; sensitivity (identifies respondents who are distressed as different from those who are not); and test-retest reliability (questionnaire performs similarly on more than one occasion when the underlying condition is unchanged). A further aim was to determine whether the draft IBD-DS correlated with the validated Diabetes Distress Scale (DDS) (7) and with the HADs. analyze data. After data analysis (see results section), the draft IBD-DS was reduced to 28 items ( Fig.1 
Boxes F & G).
Phase 3
Confirming construct validity and reliability (reproducibility) (Fig.1 Boxes H & I)
The test-retest phase was repeated with the 28-item questionnaire and a new cohort of community-based participants using identical processes as described above for Phase 2. As the purpose was to confirm the reproducibility, further associations with the DDS 35 were not tested.
Statistical methods
Data from the various scores were summarized using mean and standard deviation (normal distribution), and median and inter-quartile range (positively skewed distribution). Analyses of the association between the IBD-DS scale and HADS 36 were performed using Pearson's correlation, and was restricted to the Phase 2 'test' data only.
The internal consistency of the items making up the IBD-DS scale were assessed using Cronbach's alpha.
A high value (close to +1) would suggest good internal consistency of the score.
Two A second repeatability analysis examined agreement using the intra-class correlation (ICC) method. This method divides the total variability in the IBD-DS measurements into two sources: the variation between patients, and the variation in repeat measurements of the same patient. The ICC is the proportion of total variation that is between patients. If there is good agreement between patients, there should be little variability between repeat measurements of the same patient, and thus most variability should be between patients, giving ICC values close to 1.
A final analysis examined patterns between individual items within the scale using a factor analysis. The importance of the factors identified was determined by the size of the eigenvalue associated with each factor. Factor loadings were given a Varimax rotation to aid interpretation of results. Items with factor loadings of 0.5 or higher were deemed to be associated with a particular factor.
Ethical considerations
Ethical approval for this study was granted by the NRES Committee South West -Cornwall & Plymouth 
RESULTS
Demographic details of all study participants are provided in Table 1 .
Phases 1 and 2
Of the 297 people who initially volunteered for Phases 1 and 2, 24 could not take part (n=18 could not be contacted, n=4 had changed their minds about taking part, and n=2 had died). Fifteen people participated in cognitive interviews in Phase 1, and following initial item reduction, three further cognitive interviews were conducted to verify the changes to the questionnaire. 273 people received the 55-item test draft IBD-DS in 
Secondary item reduction
Further statistical analysis using weighted kappa, calculation of mean scores and percentage of non-zero scores, and observation of response rates was conducted. Principle Component Factor Analysis was not used at this stage because there was no pre-defined grouping of the items, making even a partial confirmatory factor analysis difficult to perform.
Following team discussion, a further 27 items were removed resulting in a 28-item final IBD-DS (each item scored 0-6, score range 0-168), plus three supplementary unscored questions. This version was circulated to a sub-sample of Phase 2 participants who had returned their test-retest questionnaires promptly (n=20).
Twelve responded, endorsing the changes.
Phase 3
Of the 209 people who volunteered for Phase 3 and received the 28-item test final IBD-DS, 123 (58.8%) responded. Of these 95 (77%) returned the retest final IBD-DS.
Data summaries and correlation between scores
Test and retest data for Phase 3 are summarised in Table 3 . IBD-DS scores were approximately normally distributed suggesting an absence of a floor or ceiling effect.
Construct validity
Examination of the association between the IBD-DS score and the HADS 36 , HBI 45 and SCCAI 46 revealed that higher IBD-DS values were associated with higher values on all other measures. The highest correlation (r = 0.77) was with the stand-alone self-reported distress item of the IBD-DS [ Table 2 ], although there were correlations with both HADS scores (anxiety, r = 0.68; depression, r = 0.62) as well (all p<0.001).
Internal consistency
The calculated value for Cronbach's alpha was 0.95, and for Guttman's Lambda 2 statistic was 0.94. Both suggest that the final IBD-DS scale has a high degree of internal consistency.
Reproducibility and stability over time (repeatability)
There were 95 participants with both test and retest data. Of these, 19 experienced a change in their disease activity (remission to relapse, or vice versa) between test and retest and three had significant missing data. These participants were excluded from the test-retest analysis. Two analyses were Clinical judgement is required as to whether this is an acceptable amount of variation.
Factor analysis
Factor analysis identified four factors, with importance indicated by eigenvalue. Factor 1 (eigenvalue 13. 
DISCUSSION
The IBD-DS demonstrates good content validity, internal consistency, construct validity, moderate reliability (agreement and reproducibility), and absence of floor and ceiling effects (≤ 15% of respondents achieved the highest or lowest possible scores). The remaining criteria (responsiveness to change and interpretability) will be addressed in full psychometric validation during future intervention studies. A particular strength of the new scale is the robust developmental process which has included our PPI team throughout, ensuring that the IBD-DS reflects the needs and concerns of patients with IBD 48 . The scale can be printed on a single sheet (two sides) of paper (A4), and scoring and identification of the patient's priority issues is rapid.
There are some similarities between items of the IBD-DS and those of the DDS. This is unsurprising given the key role of the DDS in the early development of items for the IBD-DS 16 . The DDS domains (emotional burden, physician-related distress, regimen-related distress, and interpersonal distress) were not identified as separate domains in the IBD-DS, yet the final items of IBD-DS are similar to the DDS in terms of treatment/regimen distress and in emotional/psychosocial burden. Differences appear to relate to the role of others in each disease. In diabetes, over-monitoring and criticism by family members 51 can cause distress and are contained within the interpersonal distress items of the DDS as a result of the surveillance role close family and friends feel the need to perform. In IBD it is the perceived burden of the disease on family that causes the distress. Both are socially constructed distresses but with different roots. Diabetes does not appear to limit peoples' life choices in the way that IBD does. This may relate to a perceptions of good public awareness of diabetes in contrast to IBD.
Inflammatory bowel disease is manifested in many complex symptoms which have a negative impact on patients' quality of life (QoL). The IBD-DS is an addition to a range of disease-specific patient-reported outcome measures (PROMs) which assess, for example, and QoL . Generic and disease-specific measures may also assess different but equally important aspects of disease impact, and can therefore be used together to gain a composite view 56 . Test data analysis shows IBD-DS scores to have a significant positive correlation (all p<0.001) with existing validated tools. Indications are that the new IBD-DS detects and measures disease-related distress in IBD, as the DDS 35 does for diabetes 6 . The significant correlation with both HADS scores is indicative of the inter-relationship often co-exists in chronic illnesses 12, 13 . This symptom overlap is potentially considerable and is complex for patients and
clinicians to unravel what is physical disease (IBD), psychiatric diagnosis (clinical depression) psychological morbidity (depressive symptoms) and emotional consequences of living with physical disease (IBDdistress). Disease specific distress is conceptually different from other commonly assessed patient reported outcomes such as quality of life and depression, because it derives purely from the disease itself and not from any extraneous factors. Different types of intervention may be required to manage it 6 . The IBD-DS addresses distress associated with the unique features of living with this specific disease, rather than the more generic aspects of emotional wellbeing addressed in the HADS. Previous identification of IBD-related concerns [57] [58] [59] identify bothersome issues amongst IBD populations but do not assess the impact of these issues on the individual.
Establishing cut-off points
Further work is needed to establish cut-off points. The normal distribution of scores suggests that there is a range of experience of distress amongst IBD patients. Elevated diabetes distress across diabetes populations are around 22% 5 and it is therefore to be expected that many people with IBD will not experience levels of distress that impact their self-management. Cut-off points, denoting no, mild, moderate and severe distress, may emerge from future studies. Data from a larger, more generalized study population would establish clinically concerning levels of distress for IBD which might inform scoring by determining the threshold at which distress levels would warrant clinical attention. A single summative score is indicated by statistical analysis which did not support retaining separate domains.
Clinical usefulness
Disease-related distress impacts on clinical outcomes and self-care behaviours in numerous other longterm conditions 3, 12, 13 . A recent European-wide survey of people with IBD reports the immense impact the illness has, and that patients do not always have the opportunity to raise their concerns during clinical consultations 60 . The availability of the IBD-DS to assess disease-related distress offers patients a means of indicating and prioritising their concerns, and gives clinicians a guide to understand how best to support the patient. Assessing distress levels routinely in IBD consultations may inform clinical decision-making by providing insight into the impact of IBD or a specific treatment on distress levels, and reveal the extent of distress amongst this population. Alleviating IBD-distress has the potential to improve patient QoL and improve their clinical outcomes.
Psychological therapies have been shown to be beneficial for disease-related distress in cancer [61] [62] [63] [64] , and have been used for psychological distress (anxiety and/or depression) in IBD 65 , although evidence for the latter is conflicting 66 and therapies were not used specifically for disease-related distress. In diabetes, interventions addressing psychological and education needs, delivered by the clinical disease specialist team rather than by psychology specialists, are most effective 8 . Evidence of the relationship between distress, clinical outcomes, self-management behaviors, and therapeutic interventions could support the introduction and routine availability of psychological / counselling / education support services for IBD patients.
Strengths and Limitations
This study has benefitted from patient (PPI) team involvement which has carried through from our preliminary phase 16 . PPI engagement and contribution at all stages of project design, delivery and reporting strengthens the relevance of the IBD-DS in ensuring it meets and reflects the needs and concerns of patients. There has also been considerable qualitative work to generate and reduce items, and these developmental processes are reported robustly.
There are also some limitations to consider. Phase1 and 2 participants were recruited from only two tertiary care hospitals which receive referrals from a wide geographical area; overall, patients may have a more complex disease than those attending regional services, and may also therefore experience higher levels of distress. Phase 3 participants were recruited from a single IBD charity whose membership profile is predominantly middle-income, white female. Social class, with its relationship to education, may influence ability to access social support, and thus mitigate disease-related distress to some extent. The overall sample includes a higher proportion of women, and of patients with CD, and thus may not be representative of the wider IBD population. Conversely, this may suggest that distress is associated more with CD than with UC, prompting those with CD to participate. Although Asian and Afro-Caribbean groups were represented, the majority of participants were Caucasian.
We only had self-reported disease activity scores on which to assess if IBD was in remission or relapse.
Disease scores are known not to be highly correlated with objective measures of inflammation 67 , so our definition of "stable disease" between test and retest is possibly open to inaccuracy. Further, the low cut off point for remission (≤ 4) excludes patients who are clinically in remission but score ≥5 due to permanent extra-intestinal manifestations. Finally, the amendment to the DDS (using the acronym 'IBD' in place of the word 'diabetes') was not tested for validity prior to use.
Conclusion
The 28-item IBD-DS has face and content validity with people with IBD. During refinement it has performed well alongside existing validated measures of disease-specific (diabetes) distress and symptoms of anxiety and depression. The IBD-DS offers a useful clinical and research tool for assessing IBD-distress. Further testing, to include responsiveness to change and determining cut-off points is needed. 
